Younes Jourani, Head Medical Physicist in Radiotherapy at Institut Jules Bordet, shared a post on LinkedIn:
” A new milestone for Radiation Oncology at Institut Jules Bordet / Hôpital Universitaire de Bruxelles (H.U.B) – Academisch Ziekenhuis Brussel (H.U.B)
I am thrilled to share that we have treated the first patients on the Elekta Evo using CBCT-based online adaptation with Elekta ONE | Online at Institut Jules Bordet.
With this, our institution becomes the 3rd institution worldwide to implement this technology within a fully clinical workflow.
Bringing such an advanced technique from concept to daily clinical practice is never the work of one person. It represents weeks and months of collaboration, validation, quality assurance, training, and teamwork across multiple disciplines.
I would like to sincerely thank everyone who contributed to this achievement:
- Medical Physics team – for their rigor, creativity, and relentless focus on safety and quality. Special thanks to Zelda Paquier, who led this exciting implementation project from the beginning, and Sara Poeta, her partner in crime.
- Radiation Oncologists – for their commitment and clinical leadership, particularly Dr Nicolas Jullian and Dr Robbe Van den Begin, who led the medical aspects of the implementation alongside Zelda.
- RTTs – for their engagement and adaptability, especially Margarida Costa, who worked closely with us on clinical workflows.
- Elekta teams – our partners who supported the technical implementation and training.
This milestone would not have been possible without your expertise, dedication, and team spirit.
I would also like to extend my gratitude to Renaud WITMEUR and Chloé Spilleboudt for their continued trust and commitment to investing in innovation, advanced technologies, and the future of the Radiation Oncology department. Their support enables us to push boundaries while maintaining the highest standards of patient care.
Implementing cutting-edge technology is not just about being early adopters – it is about continuously improving treatment precision, safety, and outcomes for our patients.
Proud of what we achieved together – and excited for what comes next.”